The present invention provides a method for treating spasticity in a subject. The method includes direct administration of a herpes simplex virus 1 (HSV-1) vector harboring a glutamic acid decarboxylase (GAD) gene (preferably. GAD67) into one or more dermatomes of the subject.

The disclosure provides a non-natural herpes simplex virus (HSV), compositions comprising, or alternatively consisting essentially of, or yet further consisting of the HSV, and methods of producing the HSV, or infecting a cell with the HSV. Also provided herein are methods of treating cancer or inhibiting the growth or metastasis of cancer cell in a subject in need thereof.

The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.

The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene and (ii) an immune stimulatory molecule-encoding gene.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide (e.g., a human CFTR polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of a chronic lung disease, such as cystic fibrosis); and articles of manufacture or kits thereof.

The present invention is directed to nucleic acids, vectors, compositions, kits, and cell lines comprising US11 5 leader sequence (SEQ ID NO: 1 or SEQ ID NO: 4). UL27 5 leader sequence (SEQ ID NO: 7 or SEQ ID NO: 10), or UL19 5 leader sequence (SEQ ID NO: 13 or SEQ ID NO: 16) whereby the leader sequences are capable of enhancing translation of a downstream gene encoding a protein of interest, resulting in increased protein production, expression or synthesis in HSV1 infected cells. The 5 leader increases protein expression by several fold compared to protein expression in the absence of the leader sequence. Methods of increasing protein production, methods of increasing efficiency of existing gene therapies, and methods of treating a medical condition, cellular defect, disease or disorder are also provided.

The present application relates to viral sensitizers. More specifically, the present application relates to neddylation-activating enzyme inhibitors, as well as processes for their preparation and methods of using such compounds and compositions as viral sensitizers. The present application includes a method of increasing permissiveness of a cell to a virus or genetic material encoding components of the virus, comprising administering an effective amount of a neddylation-activating enzyme (NAE) inhibitor, or a salt, solvate and/or prodrug thereof, to the cell.

The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.